Nourish, a rapidly growing virtual nutrition-focused healthcare platform, has raised $100 million in a Series C funding round as the company accelerates its expansion into comprehensive metabolic healthcare services. The funding marks a significant milestone for the four-year-old digital health company, which has increasingly positioned itself at the intersection of nutrition, obesity management, and AI-powered virtual care.
The investment round was led by Menlo Ventures, with participation from major investors including Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, and Y Combinator.
Founded as a virtual platform connecting patients with registered dietitians, Nourish has steadily expanded its healthcare model to address the growing demand for metabolic health management. The company is now broadening its services by integrating physicians into its care network and offering additional clinical support such as laboratory testing, GLP-1 medication management, and wider virtual healthcare consultations.
According to company officials, demand for physician-led services has already exceeded current capacity, resulting in an active waitlist for appointments. Nourish stated that it plans to significantly scale physician recruitment and expand care delivery capabilities through the end of 2026.
Artificial intelligence remains a central pillar of the platform’s growth strategy. Nourish has developed AI-enabled tools designed to support both patients and healthcare professionals through its mobile application. Patients are provided access to an AI-powered health assistant capable of supporting meal planning, appointment scheduling, lab interpretation, wellness coaching, and ongoing health management. For clinicians, the company has implemented AI-driven documentation systems, messaging tools, research support platforms, and recommendation engines trained on historical clinical interactions to streamline workflows and improve care efficiency. The company has also expanded its GLP-1 companion care program, which combines medical nutrition therapy with obesity medications increasingly being prescribed for weight management and metabolic disease treatment. Company executives noted that approximately 15 percent of Nourish users are currently enrolled in GLP-1-based treatment pathways. Unlike several emerging digital health providers focused on medication-driven revenue models, Nourish stated that its strategy emphasizes access to brand-name GLP-1 medications through insurance-supported coverage or at-cost pricing structures rather than generating profits directly from prescriptions. The company also highlighted findings from a 2024 peer-reviewed analysis suggesting that patients participating in Nourishes integrated GLP-1 support program achieved stronger weight-loss outcomes and improved medication adherence compared to patients outside the platform. Nourish reported that it achieved profitability in 2025 and has now secured a total of $215 million in funding since its inception. The latest investment reflects growing investor confidence in the future of integrated metabolic healthcare, where nutrition, digital medicine, behavioral support, and AI-driven clinical care are increasingly converging into a unified virtual.
By
HB Team
